

Vanda Markovic-Pekovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1899036/publications.pdf>

Version: 2024-02-01

43
papers

1,428
citations

279487

23
h-index

360668

35
g-index

43
all docs

43
docs citations

43
times ranked

1276
citing authors

#	ARTICLE	IF	CITATIONS
1	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. <i>Current Medical Research and Opinion</i> , 2020, 36, 301-327.	0.9	111
2	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. <i>Frontiers in Pharmacology</i> , 2014, 5, 106.	1.6	107
3	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	1.3	102
4	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. <i>Life</i> , 2021, 11, 528.	1.1	95
5	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , 2017, 35, 1271-1285.	1.7	94
6	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , 2013, 4, 39.	1.6	75
7	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. <i>Frontiers in Pharmacology</i> , 2018, 8, 942.	1.6	70
8	Initiatives to reduce nonprescription sales and dispensing of antibiotics: Findings and implications. <i>Journal of Research in Pharmacy Practice</i> , 2017, 6, 120.	0.2	70
9	Are pharmacists’s good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 13, 240-245.	0.9	53
10	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , 2016, 7, 305.	1.6	48
11	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 527-540.	0.7	48
12	Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 1-26.	0.7	47
13	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. <i>Frontiers in Pharmacology</i> , 2014, 5, 109.	1.6	44
14	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , 2020, 11, 591134.	1.6	44
15	Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1130-1133.	0.9	41
16	Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 71-93.	2.0	38
17	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , 2017, 8, 497.	1.6	34
18	Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. <i>Frontiers in Pharmacology</i> , 2018, 9, 442.	1.6	33

#	ARTICLE	IF	CITATIONS
19	Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 251-261.	0.7	31
20	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. GaBI Journal, 2019, 8, 49-70.	0.4	31
21	Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research, 2021, 10, 1019-1052.	0.6	30
22	Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 661-671.	0.7	29
23	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Frontiers in Pharmacology, 2016, 7, 197.	1.6	26
24	Essential to increase the use of generics in Europe to maintain comprehensive health care?. Farmeconomia E Percorsi Terapeutici, 2012, 13, 5-20.	0.2	24
25	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. Frontiers in Public Health, 2021, 9, 671961.	1.3	22
26	Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 609-618.	0.7	15
27	Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. European Journal of Clinical Pharmacology, 2010, 66, 177-186.	0.8	12
28	Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. Pharmacoepidemiology and Drug Safety, 2009, 18, 320-326.	0.9	11
29	Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future. GaBI Journal, 2015, 4, 125-135.	0.4	10
30	Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. Medicine Access Point of Care, 2021, 5, 239920262110276.	1.0	7
31	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International, 2021, 2021, 1-16.	0.9	7
32	Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. Frontiers in Pharmacology, 0, 13, .	1.6	7
33	COVID-19, health care and self-medication issues in resource-limited settings: Findings and implications based on experiences in Ghana. Advances in Human Biology, 2021, 11, 224.	0.1	6
34	Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up. Frontiers in Pharmacology, 0, 13, .	1.6	3
35	Outpatient utilization of antibioticis in the Republic of Srpska, in 2007 and 2008. Scripta Medica, 2010, 41, 22-28.	0.0	1
36	Long-term drug use and polypharmacy among the elderly population in the Republic of Srpska, Bosnia and Herzegovina. Vojnosanitetski Pregled, 2016, 73, 435-441.	0.1	1

#	ARTICLE	IF	CITATIONS
37	The first modern pharmacy in Banja Luka: The Brammer family, three generations of pharmacists. Scripta Medica, 2020, 51, 284-291.	0.0	1
38	Pharmacoepidemiological analysis of use of medicines prescribed on the account of the Republic of Srpska health insurance fund in the period of 2003-2004. Scripta Medica, 2005, 36, 25-35.	0.0	0
39	Outpatient utilization of systemic antibiotics in the Republic of Srpska. Scripta Medica, 2013, 44, 8-13.	0.0	0
40	Vanbolnička potrošnja antibiotika u Republici Srpskoj u periodu od 2009. do 2014. Godine. Scripta Medica, 2016, 47, 48-53.	0.0	0
41	The characteristics of the outpatient utilisation of medicines in the Republic of Srpska in the period 2009-2017. Scripta Medica, 2019, 50, 167-176.	0.0	0
42	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. Scripta Medica, 2022, 53, 29-35.	0.0	0
43	Regulation of the apothecary activity in Bosnia and Herzegovina over the Austro-Hungarian period. Medicinski Glasnik, 2021, 18, 343-351.	0.3	0